NCT01069055

Brief Summary

The purpose of this study is to determine whether lornoxicam or paracetamol is more effective in providing pre-emptive analgesia for adult patients undergoing elective unilateral inguinal hernia repair under general anesthesia.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at below P25 for phase_3

Timeline
Completed

Started Feb 2010

Shorter than P25 for phase_3

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2010

Completed
15 days until next milestone

First Submitted

Initial submission to the registry

February 16, 2010

Completed
1 day until next milestone

First Posted

Study publicly available on registry

February 17, 2010

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2010

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2010

Completed
Last Updated

February 24, 2010

Status Verified

February 1, 2010

Enrollment Period

4 months

First QC Date

February 16, 2010

Last Update Submit

February 23, 2010

Conditions

Keywords

inguinal herniasurgerygeneral anesthesiaanalgesiapre-emptiveSF36

Outcome Measures

Primary Outcomes (1)

  • Postoperative pain and comfort

    24 and 48 hours

Secondary Outcomes (1)

  • Postoperative late pain complaint and quality of life

    4. week

Study Arms (3)

Placebo Control

PLACEBO COMPARATOR

Group I (Placebo Control) 100 ml intravenous saline infusion as placebo 30 minitues before the surgery.

Other: Sterile Saline

Lornoxicam

ACTIVE COMPARATOR

Group II: 8 mg intravenous lornoxicam infusion in 100 ml saline 30 minitues before the surgery.

Drug: Intravenous lornoxicam

Paracetamol

ACTIVE COMPARATOR

Group III: 1 g intravenous paracetamol infusion in 100 ml saline 30 minitues before the surgery.

Drug: Intravenous paracetamol

Interventions

Group I: 100 ml intravenous saline infusion as placebo 30 minitues before the surgery.

Also known as: Saline
Placebo Control

Group II: 8 mg intravenous lornoxicam infusion in 100 ml saline 30 minitues before the surgery.

Also known as: Lornoxicam: Xefo
Lornoxicam

Group III: 1 g intravenous paracetamol infusion in 100 ml saline 30 minitues before the surgery.

Also known as: Paracetamol: Perfalgan
Paracetamol

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • inguinal hernia
  • unilateral hernia
  • general anesthesia
  • elective repair

You may not qualify if:

  • drug allergy
  • bilateral hernia
  • local anesthesia
  • local blockade
  • regional anesthesia
  • emergency surgery
  • complicated hernia
  • recurrent hernia

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Diskapi Teaching and Research Hospital

Ankara, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Hernia, InguinalPain, PostoperativeAgnosia

Interventions

Sodium Chloride

Condition Hierarchy (Ancestors)

Hernia, AbdominalHerniaPathological Conditions, AnatomicalPathological Conditions, Signs and SymptomsPostoperative ComplicationsPathologic ProcessesPainNeurologic ManifestationsSigns and SymptomsPerceptual DisordersNeurobehavioral ManifestationsNervous System Diseases

Intervention Hierarchy (Ancestors)

ChloridesHydrochloric AcidChlorine CompoundsInorganic ChemicalsSodium Compounds

Study Officials

  • Ercan Sonmez, MD

    Diskapi Teaching and Research Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

February 16, 2010

First Posted

February 17, 2010

Study Start

February 1, 2010

Primary Completion

June 1, 2010

Study Completion

June 1, 2010

Last Updated

February 24, 2010

Record last verified: 2010-02

Locations